First AD

Second AD

Panelists discuss the differences in mechanisms of action among the FDA-approved Janus kinase (JAK) inhibitors for alopecia, including baricitinib, deuruxolitinib, and ritlecitinib, and explore how selective inhibition differs from pan-inhibition in influencing treatment efficacy.

JAK Inhibition in the Treatment of Alopecia Areata

Video content above is prompted by the following:

Three JAK inhibitors are FDA-approved for the treatment of alopecia: baricitinib and deuruxolitinib (JAK1/2 inhibitors), and ritlecitinib (selective JAK3 and TEC inhibitor). Can you talk about the differences in mechanisms of action and how they might influence treatment efficacy for alopecia?

How does selective inhibition differ from pan-inhibition?

Recent Advances in the Treatment of Alopecia Areata

Medcast Videos

Recent Advances in Treatment of Alopecia Areata

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Peer Exchange

JAK inhibitors, including baricitinib, deuruxolitinib, and ritlecitinib, are FDA-approved for alopecia treatment, each with distinct mechanisms of action. Baricitinib and deuruxolitinib target JAK1/2, while ritlecitinib selectively inhibits JAK3 and TEC. These differences in selectivity may influence treatment efficacy and safety profiles. Selective inhibition targets specific JAK pathways, potentially reducing off-target effects, whereas pan-inhibition affects multiple JAK pathways, which may increase efficacy but also the risk of adverse effects. Understanding these distinctions is crucial for optimizing therapeutic strategies in alopecia management.